Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 3, 2011, Pages 302-307

  Bechard, Jeff ^a   Gibson, John Ken ^a   Killingsworth, Cheryl R ^b   Wheeler, Jeffery J ^a   Schneidkraut, Marlowe J ^c   Huang, Jian ^b   Ideker, Raymond E ^b   McAfee, Donald A ^a  

^a Cardiome Pharma Corp   (Canada)

^b University of Alabama at Birmingham   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

antiarrhythmics; effective refractory period; ventricular defibrillation threshold; vernakalant

Indexed keywords

VERNAKALANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATION THRESHOLD; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SELECTIVITY; HEART ATRIUM; HEART MUSCLE REFRACTORY PERIOD; HEART RIGHT ATRIUM; HEART RIGHT VENTRICLE; HEART VENTRICLE; HEART VENTRICLE FIBRILLATION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTRIC COUNTERSHOCK; HEART ATRIA; HUMANS; MALE; POTASSIUM CHANNELS; PYRROLIDINES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SODIUM CHANNELS; SWINE; VENTRICULAR FUNCTION;

EID: 79952816640     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182073c94     Document Type: Article

References (19)

1. Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a Phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-1525. (Pubitemid 351440640)
2. Torp-Pedersen C, Karpenko Y, Raev D, et al. Oral vernakalant for the prevention ofatrial fibrillation recurrence post-cardioversion. Eur Heart J. 2009;30(abstract suppl):450.
3. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005; 16:1227-1238.
4. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007;16:519-532. (Pubitemid 46554469)
5. Orth PM, Hesketh JC, Mak CK, et al. RSD1235 blocks late INa and suppresses early after depolarizations and torsades de pointes induced by Class III agents. Cardiovasc Res. 2006;70:486-496.
6. Beatch GN, Helmes M, Blaauw Y, et al. Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria-selective antiarrhythmic drug, RSD1235, in the goat Circulation. 2004;110:III-163.
7. Beatch GN, Shinagawa K, Johnson B, et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. Pharmacologist. 2002;44(Suppl 1):A15.
8. Carnes CA, Medirad AA, Nelson SD. Drug and defibrillator interactions. Pharmacotherapy. 1998;18:516-525. (Pubitemid 28228335)
9. Qi X, Dorian P. Antiarrhythmic drugs and ventricular defibrillation energy requirements. Chin Med J (Engl). 1999;112:1147-1152. (Pubitemid 30004517)
10. Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68:607-630. (Pubitemid 351451540)
11. Dixon WJ. The up-and-down method for small samples. JAm Stat Assoc 1965;60:967-978.
12. Mao ZL, Wheeler JJ, Clohs LL, et al. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1325): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009;49:17-29.
13. Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35-40. (Pubitemid 47220444)
14. Dorian P, Fain ES, Davy JM, et al. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. JAm Coll Cardiol. 1986;8:327-332. (Pubitemid 16036466)
15. Hernandez R, Mann DE, Breckinridge S, et al. Effects of flecainide on defibrillation thresholds in the anesthetized dog. JAm Coll Cardiol. 1989; 14:777-781.
16. Wang M, Dorian P. DL and D sotalol decrease defibrillation energy requirements. Pacing Clin Electrophysiol. 1989;12:1522-1529. (Pubitemid 19221907)
17. Davis DR, Beatch GN, Dickenson DR, et al. Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Can J Cardiol. 1999;15:193-200. (Pubitemid 29132095)
18. Ujhelyi MR, Schur M, Frede T, et al. Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance. J Am Coll Cardiol. 1996;27: 1534-1542. (Pubitemid 26153287)
19. Page R. Medical management ofatrial fibrillation: future directions. Heart Rhythm. 2007;4(Suppl 3):S91-S94.